Description of service

Intravacc has several detoxified LPS variants available for testing with your antigen of choice. The LPS adjuvant platform technology of Intravacc is open for new collaborations, which can range from out-licensing to large collaborative development, process optimization and cGMP production.


Earliest start date October 2017.


Dr. Peter van der Ley


Formulation of antigens in LPS adjuvants


Services do NOT include

Animal immunisation experiments.

Sample Requirements - input of users

Antigens of sufficient purity to make addition of LPS adjuvants meaningful.

Lead Scientist

Dr. Peter van der Ley

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2021 European Vaccine Initiative. Designed by European Vaccine Initiative